| Literature DB >> 22222098 |
Yin Xue Sun1, Yan Xin Huang, Feng Li Li, Hong Yan Wang, Cong Fan, Yong Li Bao, Lu Guo Sun, Zhi Qiang Ma, Jun Kong, Yu Xin Li.
Abstract
BACKGROUND: The virtual screening (VS) of lead compounds using molecular docking and pharmacophore detection is now an important tool in drug discovery. VS tasks typically require a combination of several software tools and a molecular graphics system. Thus, the integration of all the requisite tools in a single operating environment could reduce the complexity of running VS experiments. However, only a few freely available integrated software platforms have been developed.Entities:
Year: 2012 PMID: 22222098 PMCID: PMC3264508 DOI: 10.1186/1752-153X-6-2
Source DB: PubMed Journal: Chem Cent J ISSN: 1752-153X Impact factor: 4.215
Figure 1Architecture of the IVSPlat 1.0 VS platform.
Figure 2Main applications of the IVSPlat 1.0 VS platform. (a) Main screen of the IVSPlat 1.0 platform. (b) Preparation of receptor binding site(s). (c) Preparation of ligand database. (d) Definition of the grid box. (e) Docking-based VS panel with the docked results shown in a table. (f) Pharmacophore-based VS panel with the results listed in a table. (g) Clustering panel and clustering results displayed as a dendrogram. (h) Database management.
Figure 3EF of docking-based VS and the corresponding percentage of active compounds. EF of docking-based VS. (b) The corresponding percentage of active compounds.
Figure 4EF and corresponding percentages of active compounds with pharmacophore-based VS using the fourth and first datasets. (a-1) EF of pharmacophore-based VS with the fourth experimental dataset. (a-2) The corresponding percentages of active compounds with the fourth experimental dataset. (b-1) Enrichment factor when screening the first experimental dataset. (b-2) The corresponding percentages of active compounds when screening the first experimental dataset. The plot shows the results with four ligand groups: 32 ligands (blue); 16 ligands (red); 8 ligands (green); and 4 ligands (purple).
Screening results with the fourth dataset for the top 50% of the database using dock- and pharmacophore- based VS, and a combination of both
| No | Dock | Phar | Both | No | Dock | Phar | Both | No | Dock | Phar | Both |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | √ | x | x | 25 | √ | √ | √ | 49 | √ | √ | √ |
| 2 | √ | √ | √ | 26 | x | √ | x | 50 | √ | √ | √ |
| 3 | √ | √ | √ | 27 | √ | √ | √ | 51 | √ | √ | √ |
| 4 | √ | √ | √ | 28 | √ | √ | √ | 52 | √ | √ | √ |
| 5 | √ | x | x | 29 | √ | √ | √ | 53 | √ | √ | √ |
| 6 | √ | x | x | 30 | √ | √ | √ | 54 | √ | √ | √ |
| 7 | √ | x | x | 31 | √ | √ | √ | 55 | √ | √ | √ |
| 8 | √ | x | x | 32 | √ | √ | √ | 56 | √ | √ | √ |
| 9 | x | √ | x | 33 | √ | √ | √ | 57 | √ | √ | √ |
| 10 | x | √ | x | 34 | √ | √ | √ | 58 | x | √ | x |
| 11 | √ | √ | √ | 35 | x | √ | x | 59 | x | √ | x |
| 12 | √ | √ | √ | 36 | √ | √ | √ | 60 | x | √ | x |
| 13 | √ | √ | √ | 37 | √ | √ | √ | 61 | √ | √ | √ |
| 14 | √ | √ | √ | 38 | √ | √ | √ | 62 | √ | x | x |
| 15 | √ | √ | √ | 39 | √ | √ | √ | 63 | √ | √ | √ |
| 16 | √ | √ | √ | 40 | √ | √ | √ | 64 | √ | √ | √ |
| 17 | √ | √ | √ | 41 | √ | √ | √ | 65 | √ | √ | √ |
| 18 | √ | √ | √ | 42 | √ | √ | √ | 66 | √ | √ | √ |
| 19 | √ | √ | √ | 43 | √ | √ | √ | 67 | √ | √ | √ |
| 20 | √ | √ | √ | 44 | √ | √ | √ | 68 | √ | √ | √ |
| 21 | √ | √ | √ | 45 | √ | √ | √ | 69 | √ | √ | √ |
| 22 | √ | √ | √ | 46 | √ | √ | √ | 70 | √ | √ | √ |
| 23 | √ | √ | √ | 47 | √ | √ | √ | 71 | √ | √ | √ |
| 24 | √ | √ | √ | 48 | √ | √ | √ | 72 | √ | x | x |
In the table, Nos 1 to 72 represent ligands 1 to 72. "√" indicates that the ligand was successfully screened out, whereas "×" indicates that the ligand was not screened out.
Figure 5Number of ligands identified by docking- and pharmacophore- based VS, and a combination of both, with the fourth dataset for the top 50% of the database. "Fail of both" indicates the number of ligands we failed to identify using both methods.